Standard of Care Versus Hemopatch® During Liver Resection

Inclusion Criteria: * Age: ≥18 years. * Patients with an indication for open liver resection (segmental or non-segmental). * Target bleeding site of generalized bleeding that persists on the cut surface of the liver in which hemostasis cannot be achieved by conventional methods. * Willing and able to complete the clinical trial procedures, as described in the protocol. * Signed written informed consent to participate in this clinical trial. Exclusion Criteria: * Presence of coagulation disorder, Klatskin tumour. Cirrhosis, re-hepatectomies and biliary resections * Concurrent participation in another clinical trial with a medical device or medicinal product or with interfering endpoints. * Concurrent or previous therapy with systemic pharmacologic agents promoting blood clotting including but not limited to tranexamic acid, activated factor VII, fibrinogen and aprotinin. * Known allergy or hypersensitivity to a component of the investigational treatments Hemopatch® ,to riboflavin or to proteins of bovine origin. * Pregnancy or breast-feeding. * Inability to understand the nature and the extent of the trial and the procedures required. Criteria to be checked during surgery (intraoperative exclusion criteria): * Infected wound area. * Persistent major bleeding after primary hemostasis.